S-1 vs Capecitabine in the Elderly and/or Poor Performance Status Patients With Recurrent or Metastatic Gastric Cancer

The recruitment status of this study is unknown because the information has not been verified recently.
Verified December 2007 by National Cancer Center, Korea.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
National Cancer Center, Korea
ClinicalTrials.gov Identifier:
NCT00580359
First received: December 21, 2007
Last updated: December 26, 2007
Last verified: December 2007
  Purpose

This study is an open-label, single-center, and randomized phase II study designed to evaluate each efficacy and safety of S-1 and capecitabine in the elderly and/or poor performance status patients with recurrent or metastatic gastric cancer. The randomization will be stratified by age (70-85 years versus 65 years and < 70 years) and performance status, which is dependent on age group; in 70-85 years, ECOG performance status 0-1 versus 2 and in ³65 years and <70 years, ECOG performance status 2 versus 3.

  • S-1 40mg/m2 orally twice daily on days 1 (evening) - 15 (morning)
  • Capecitabine 1250mg/m2 orally twice daily on days 1 (evening) - 15 (morning) Treatment will be administered every 3 weeks and will be continued in the absence of disease progression or unacceptable toxicity.

Condition Intervention Phase
Stomach Neoplasms
Drug: S-1, capecitabine
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Randomized Phase II Study of S-1 Versus Capecitabine as First-Line Chemotherapy in the Elderly and/or Poor Performance Status Patients With Recurrent or Metastatic Gastric Cancer

Resource links provided by NLM:


Further study details as provided by National Cancer Center, Korea:

Primary Outcome Measures:
  • To evaluate each response rate of S-1 and capecitabine in the elderly and/or poor performance status patients with recurrent or metastatic gastric cancer [ Time Frame: During Chemotherapy ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • the duration of response, time to progression, progression-free survival,overall survival,the safety profiles,the quality of life,the CYP2A6 genetic polymorphism and its association with clinical outcomes in patients treated with S-1 [ Time Frame: During study period ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 96
Study Start Date: May 2007
Estimated Study Completion Date: June 2010
Estimated Primary Completion Date: December 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: A
S-1 40mg/m2 orally twice daily on days 1 (evening) - 15 (morning)
Drug: S-1, capecitabine
S-1 40mg/m2 orally twice daily on days 1(evening) - 15 (morning)every 3 weeks, until disease progression, Capecitabine 1250mg/m2 orally twice daily on days 1 (evening) - 15 (morning)every 3 weeks, until disease progression
Active Comparator: B
Capecitabine 1250mg/m2 orally twice daily on days 1 (evening) - 15 (morning)
Drug: S-1, capecitabine
S-1 40mg/m2 orally twice daily on days 1(evening) - 15 (morning)every 3 weeks, until disease progression, Capecitabine 1250mg/m2 orally twice daily on days 1 (evening) - 15 (morning)every 3 weeks, until disease progression

  Eligibility

Ages Eligible for Study:   60 Years to 85 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Histologically or cytologically confirmed gastric adenocarcinoma with recurrent or metastatic disease
  2. Age of 70-85 years with Eastern Cooperative Oncology Group (ECOG) performance status 0-2 or age ≥65 and <70 with ECOG performance status ≥ 2
  3. Measurable disease as defined by Response Evaluation Criteria In Solid Tumors (RECIST) Measurable lesions:

    • Lesions that can be accurately measured in at least one dimension by any of the following:

      • Computed tomography (CT) of abdomen, pelvis or thorax, if the longest diameter to be recorded is at least 10 mm with spiral CT
      • Chest x-ray, if the lung lesion to be recorded is clearly defined and surrounded by aerated lung and the diameter to be recorded is at least 20 mm- Physical examination, if the clinically detected lesions are superficial (e.g., skin nodule and palpable lymph nodes) and at least 10 mm
  4. No prior chemotherapy for recurrent and/or metastatic disease (prior adjuvant/neoadjuvant chemotherapy is allowed at least 6 months has relapsed between completion of adjuvant/neoadjuvant therapy and enrolment into the therapy; prior S-1 or capecitabine is not allowed)
  5. Adequate major organ function including the following:

    • Hematopoietic function:

      • absolute neutrophil count (ANC)≥1,500/mm3,
      • Platelet ≥ 100,000/mm3,
    • Hepatic function:

      • serum bilirubin =< 1.5 x upper limit of normal (ULN),
      • AST/ALT levels =< 2.5 x ULN ( 5 x ULN if liver metastases are present)
    • Renal function:

      • serum creatinine =< 1.5 x ULN
  6. Patients should sign a written informed consent before study entry

Exclusion Criteria:

  1. Lack of physical integrity of the upper gastrointestinal tract or malabsorption syndrome (e.g. patients with partial or total gastrectomy can enter the study, but not those with a jejunostomy probe), or inability to take oral medication
  2. Patients with active (significant or uncontrolled) gastrointestinal bleeding
  3. Inadequate cardiovascular function:

    • New York Heart Association class III or IV heart disease
    • Unstable angina or myocardial infarction within the past 6 months
    • History of significant ventricular arrhythmia requiring medication with antiarrhythmics or significant conduction system abnormality
  4. Serious concurrent infection or nonmalignant illness that is uncontrolled or whose control may be jeopardized by complications of study therapy
  5. Other malignancy within the past 3 years except non-melanomatous skin cancer or carcinoma in situ of the cervix
  6. History of or current brain metastases
  7. Psychiatric disorder that would preclude compliance
  8. Known dihydropyrimidine dehydrogenase deficiency
  9. Patients receiving a concomitant treatment with drugs interacting with S-1 or capecitabine such as flucytosine, phenytoin, warfarin, lamivudine, or allopurinol et al.
  10. Patients with known active infection with HIV, HBV, or HCV
  11. Major surgery within 4 weeks of start of study treatment, without complete recovery
  12. Radiotherapy within 4 weeks of start of study treatment; 2 weeks interval allowed if palliative radiotherapy was given to bone metastatic site and patient recovered from any acute toxicity
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00580359

Contacts
Contact: Sook Ryun Park, M.D. +82-31-920-1609 sukryun73@ncc.re.kr
Contact: So Yun Park, MS +82-31-920-2309 tomongmong@naver.com

Locations
Korea, Republic of
National Cancer Center Korea Recruiting
Goyang, Gyeonggi, Korea, Republic of
Contact: Sook Ryun Park, M.D    +82-31-920-1609    sukryun73@ncc.re.kr   
Contact: So Yun Park, MS    +82-31-920-2307    tomongmong@naver.com   
Sub-Investigator: Noe Kyeong Kim, M.D         
Sub-Investigator: Young Iee Park, M.D         
Sub-Investigator: Byung-Ho Nam, M.D         
Sub-Investigator: Hye Suk Han, M.D         
Sponsors and Collaborators
National Cancer Center, Korea
Investigators
Principal Investigator: Sook Ryun Park, M.D National Cancer Center, Korea
  More Information

No publications provided

Responsible Party: Sook Ryun Park, M.D., National Cancer Center, Korea
ClinicalTrials.gov Identifier: NCT00580359     History of Changes
Other Study ID Numbers: NCCCTS-07-263
Study First Received: December 21, 2007
Last Updated: December 26, 2007
Health Authority: Korea: Food and Drug Administration

Keywords provided by National Cancer Center, Korea:
Stomach Neoplasms
Secondary
Combination chemotherapy
S-1
Capecitabine

Additional relevant MeSH terms:
Stomach Neoplasms
Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Gastrointestinal Diseases
Stomach Diseases
Capecitabine
Fluorouracil
Antimetabolites, Antineoplastic
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Antineoplastic Agents
Therapeutic Uses
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on September 18, 2014